LifeSpan BioSciences, Inc. Announces Agreement With Pfizer Inc. For Expanded DrugTarget(TM) Localization Database
Published: Dec 21, 2005
SEATTLE--(BUSINESS WIRE)--Dec. 21, 2005--LifeSpan BioSciences, Inc., a leading proteomics company specializing in molecular pathology, today announced a multi-year agreement with Pfizer Inc. (NYSE:PFE). Under the terms of the agreement, Pfizer will gain access to all the features of the DrugTarget Database(TM), including informatics on more than 3200 genes, 852 comprehensive immunohistochemistry (IHC) reports with localization information on more than 400 potential drug targets selected by pharmaceutical company subscribers, and innovative search and sort tools. In addition, Pfizer will nominate at least 60 new targets to be studied by IHC and published in the consortium database. LifeSpan will continue to build the database by publishing localization data on an undisclosed number of additional targets each year.